In a patient aged 70 or older without known atherosclerotic cardiovascular disease, should routine low‑dose aspirin be used for primary prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Not Use Routine Low-Dose Aspirin for Primary Prevention in Patients ≥70 Years Without Known ASCVD

Based on the ASPREE trial and current guidelines, routine low-dose aspirin should NOT be used for primary prevention in patients aged 70 or older without atherosclerotic cardiovascular disease—the harms outweigh any potential benefits. 1, 2, 3

The Evidence Against Aspirin in This Population

The ASPREE trial specifically addressed this question in over 19,000 adults aged ≥65 years (including 56% women, median age 74 years). After a median follow-up of 4.7 years:

  • No cardiovascular benefit: Aspirin showed no reduction in cardiovascular events (10.7 vs 11.3 events per 1,000 person-years; HR 0.95% CI 0.83-1.08) 1, 2
  • Increased bleeding risk: Major hemorrhage occurred significantly more frequently with aspirin (8.6 vs 6.2 events per 1,000 person-years; HR 1.38,95% CI 1.18-1.62; P<0.001) 1, 2
  • Increased mortality: There was an unexpected increased risk of death in the aspirin group 1

Current Guideline Recommendations

The 2019 ACC/AHA Primary Prevention Guidelines provide clear direction 3:

  • Class III: Harm recommendation (Level of Evidence B-R): Low-dose aspirin (75-100 mg daily) should NOT be administered routinely for primary prevention in adults >70 years of age
  • The number needed to treat to cause major bleeding (210) is actually LOWER than the number needed to prevent an ASCVD event (265), indicating more harm than benefit 1

The 2019 ADA Diabetes Guidelines reinforce this, stating: "For patients over the age of 70 years (with or without diabetes), the balance appears to have greater risk than benefit" 2

The 2024 AHA/ASA Stroke Prevention Guidelines also recommend against aspirin in this population (Class 3: No Benefit, Level A) 4

Why Older Adults Are Different

Several factors make aspirin particularly problematic in patients ≥70 years:

  1. Higher baseline bleeding risk: Older age itself increases bleeding risk from aspirin, particularly intracranial and gastrointestinal hemorrhage 1, 5
  2. Competing risks: Life expectancy and competing causes of mortality reduce the potential for long-term cardiovascular benefit
  3. Modern preventive therapy: Contemporary trials (ASPREE, ARRIVE, ASCEND) show less benefit than older trials because patients now receive better standard preventive care including statins and blood pressure control 1

Clinical Decision-Making Algorithm

For a patient ≥70 years without known ASCVD:

Step 1: Confirm no history of MI, stroke, or other established ASCVD

  • If ASCVD present → Aspirin IS indicated for secondary prevention 2

Step 2: Assess bleeding risk factors:

  • History of GI bleeding or peptic ulcer disease
  • Thrombocytopenia or coagulopathy
  • Chronic kidney disease
  • Concurrent anticoagulants, NSAIDs, or steroids
  • Uncontrolled hypertension

Step 3: For primary prevention in patients ≥70 years:

  • Do NOT initiate aspirin regardless of ASCVD risk score 3, 4
  • Focus on proven interventions: statin therapy, blood pressure control, smoking cessation, lifestyle modification

Step 4: If patient is already on aspirin for unclear reasons:

  • Consider deprescribing, especially if bleeding risk factors present
  • Discuss risks vs. benefits with shared decision-making

Common Pitfalls to Avoid

  1. Don't use ASCVD risk calculators to justify aspirin in this age group: Even with high calculated risk, the bleeding risk outweighs benefit 2

  2. Don't confuse primary and secondary prevention: Aspirin remains strongly indicated for secondary prevention (patients WITH known ASCVD) at any age 2, 6

  3. Don't assume diabetes changes the recommendation: The ASCEND trial showed that even in diabetic patients, aspirin benefits were counterbalanced by bleeding risk, and age >70 years still represents greater risk than benefit 2

  4. Don't continue aspirin "just in case": If started inappropriately, aspirin should be discontinued unless there's a clear secondary prevention indication

The Rare Exception

The only scenario where aspirin MIGHT be considered in select patients aged 40-70 years (not >70) is when ALL of the following apply 3:

  • Very high ASCVD risk (>10% 10-year risk)
  • Low bleeding risk
  • Patient preference after shared decision-making
  • Age 40-70 years (Class IIb recommendation)

This exception does NOT apply to patients ≥70 years, where the recommendation is Class III: Harm 3, 7, 4

Related Questions

What are the 2026 ACC guideline recommendations for initiating and continuing low‑dose aspirin (81 mg) in patients over 70 years, both with and without established atherosclerotic cardiovascular disease (ASCVD)?
Should low-dose (baby) aspirin be used for primary cardiovascular prevention in a 77-year-old man with hypertension, atherosclerotic disease, and chronic obstructive pulmonary disease?
Can aspirin be administered to a patient with chest pain who has a do-not-resuscitate (DNR) order?
What are the indications, recommended dosing, contraindications, and precautions for acetylsalicylic acid (aspirin)?
Should a 66-year-old patient who began low‑dose aspirin (81 mg) at age 50 and has tolerated it well continue the medication indefinitely?
In a patient with MRI findings of a non‑displaced full‑thickness chondral delamination of the lateral femoral condyle (5 × 15 mm), mild patellar chondral fissuring, a small joint effusion with Baker's cyst, and mildly expansile semimembranosus bursitis, what symptoms are expected, and what is the appropriate treatment plan and prognosis?
What does an enlarged prostate with T2‑hypointense signal on MRI indicate, and what diagnostic and management steps should be taken?
At what blood glucose level should I call emergency services (911)?
What is the recommended empagliflozin (Jardiance) dose for patients with heart failure with preserved ejection fraction?
If a rheumatoid factor (RF) test is negative once, will it always remain negative?
What are the differences between cefazolin and ceftriaxone?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.